Insmed Incorporated (NASDAQ:INSM) Receives $83.67 Average PT from Analysts

Shares of Insmed Incorporated (NASDAQ:INSM) have received a consensus recommendation of “Buy” from the sixteen research firms that are currently covering the firm, MarketBeat.com reports. Sixteen investment analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $83.67.

A number of brokerages have issued reports on INSM. Bank of America increased their target price on shares of Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. JPMorgan Chase & Co. raised their price objective on Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research note on Friday, November 22nd. Truist Financial reiterated a “buy” rating and set a $105.00 target price (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. Finally, HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Insmed in a research report on Friday, November 1st.

Insmed Trading Down 0.6 %

Shares of INSM stock opened at $65.72 on Tuesday. Insmed has a 1-year low of $21.92 and a 1-year high of $80.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The business’s fifty day moving average price is $71.33 and its 200 day moving average price is $72.49. The firm has a market capitalization of $11.76 billion, a PE ratio of -11.84 and a beta of 1.12.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to analyst estimates of $93.36 million. During the same period in the previous year, the company earned ($1.10) EPS. The firm’s quarterly revenue was up 18.1% on a year-over-year basis. As a group, sell-side analysts forecast that Insmed will post -5.44 EPS for the current fiscal year.

Insider Transactions at Insmed

In other Insmed news, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total value of $1,309,500.00. Following the completion of the sale, the chief executive officer now owns 384,960 shares in the company, valued at $26,885,606.40. The trade was a 4.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Insmed

A number of institutional investors have recently bought and sold shares of the stock. Everence Capital Management Inc. acquired a new position in shares of Insmed in the 4th quarter valued at $352,000. Principal Financial Group Inc. raised its position in shares of Insmed by 12.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock worth $136,648,000 after buying an additional 214,130 shares during the period. Tidal Investments LLC boosted its holdings in Insmed by 447.0% in the third quarter. Tidal Investments LLC now owns 24,102 shares of the biopharmaceutical company’s stock valued at $1,759,000 after acquiring an additional 19,696 shares during the last quarter. Sanctuary Advisors LLC purchased a new stake in Insmed during the third quarter valued at about $248,000. Finally, Coldstream Capital Management Inc. acquired a new stake in Insmed during the third quarter worth about $255,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.